February 6, 2018 Uncategorized

A GE HEALTHCARE MAGYAR ÉS AMERIKAI IT SZAKEMBEREI FEJLESZTETTÉK A TÉLI OLIMPIA SPORTORVOSI ANALITIKAI RENDSZERÉT

Az alkalmazás olyan értékes információkat tesz elérhetővé egy helyen és felületen, mint például a sportoló sérüléseinek és betegségének adatai, a helyszín adatai, az alkalmazott sport- és edzési- eljárások. A felhőben tárolt információk alapján a Játékok egészségügyi személyzete átfogó képet kaphat a sportolók egészségi állapotáról, és gyors döntéseket hozhat a szükséges beavatkozás, vagy kezelés módjáról. Az... Read more

February 3, 2018 Uncategorized

Comparable Historical Revenue Schedules Inclusive of C. R. Bard Posted to BD Website

FRANKLIN LAKES, N.J., Feb. 2, 2018 /PRNewswire/ — As previously disclosed, on December 29, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX) completed the acquisition of C. R. Bard, Inc. (“Bard”).  In relation to the acquisition, BD has provided supplemental, unaudited historical financial information on the Investor page of its website at www.bd.com/investors.  This information presents... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 25, 2018 Uncategorized

Enzo Life Sciences Introduces New Portfolio of Clinically Relevant, Validated Antibodies for IHC

Enzo Life Sciences is proud to announce the introduction of three new clinically relevant antibodies for immunohistochemistry detection. When combined with Enzo’s enhanced detection system, our IHC solutions are among the most robust and cost-effective on the market. This furthers Enzo’s capabilities in the rapidly growing segment of Anatomical Pathology, and allows us to enable... Read more

January 18, 2018 Uncategorized

BD Announces Completion of Enrollment in the Lutonix™ 014 Drug Coated Balloon Below-The-Knee Trial

FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, controlled trial intended... Read more

January 17, 2018 PR/Corporate Uncategorized

BD Announces Webcast of Annual Meeting of Shareholders

FRANKLIN LAKES, N.J., Jan. 17, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2018, at 1 p.m. (ET). The webcast can be accessed from the BD corporate website at http://www.bd.com/investors/ and... Read more